Asia PE-VC Summit 2019
“Singapore, 17 and 18 September 2019
AUM Biosciences was in attendance at the Asia PE-VC Summit 2019, Southeast Asia's largest conference for private equity, venture capital and startup executives. The summit, which was held in Singapore, hosted executives from over 30 countries
AUM was represented by Mr. Vishal Doshi.
For more information, visit https://events.dealstreetasia.com/sg2019/
To stay up to date with AUM, please connect with us LinkedIn”
About AUM Biosciences
AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.
AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.
Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit www.aumbiosciences.com